Dawn Christine Maroney Sells 30,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $19.55, for a total value of $586,500.00. Following the sale, the president directly owned 947,313 shares in the company, valued at approximately $18,519,969.15. The trade was a 3.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dawn Christine Maroney also recently made the following trade(s):

• On Friday, May 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $16.09, for a total value of $482,700.00.
• On Wednesday, April 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.87, for a total value of $626,100.00.
• On Wednesday, March 18th, Dawn Christine Maroney sold 36,749 shares of Alignment Healthcare stock. The shares were sold at an average price of $17.84, for a total value of $655,602.16.

Alignment Healthcare Trading Up 4.1%

Alignment Healthcare stock opened at $20.60 on Wednesday. The stock has a 50-day moving average of $18.59 and a two-hundred day moving average of $19.43. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The stock has a market cap of $4.26 billion, a PE ratio of 228.89, a price-to-earnings-growth ratio of 2.67 and a beta of 1.14.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same period last year, the business posted ($0.05) earnings per share. The firm’s revenue was up 33.3% compared to the same quarter last year. On average, research analysts anticipate that Alignment Healthcare, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ALHC. Royal Bank of Canada raised its stake in shares of Alignment Healthcare by 92.6% in the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Alignment Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after purchasing an additional 2,594 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after purchasing an additional 429,703 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Alignment Healthcare in the first quarter worth about $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after purchasing an additional 44,452 shares during the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALHC. Wolfe Research began coverage on Alignment Healthcare in a research note on Friday, April 17th. They issued an “outperform” rating and a $24.00 price target for the company. Barclays decreased their price target on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Zacks Research upgraded Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 28th. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research note on Wednesday, June 10th. Finally, Weiss Ratings upgraded Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average price target of $24.30.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.